

Relationship of Metabolic Syndrome Indicators in Gestational Diabetes with Adiponectin Levels

Yasmin Akhtar¹, Mudassir Ahmad Khan¹, Muhammad Kashif Malik², Seemin Kashif³, Gulalai Rehman⁴

ABSTRACT

OBJECTIVE: To assess the relationship between MetS in gestational diabetes with adiponectin.

METHODOLOGY: This analytical cross-sectional study was carried out from February 2015 - January 2016 at Gynecology and Obstetrics OPDs in four public and one private tertiary care hospital in Peshawar, Khyber Pakhtunkhwa, Pakistan. Purposive sampling was done. Group one comprised 100 healthy pregnant women, while the second group included 100 pregnant women with known gestational diabetes. Women in the third trimester, with a single fetus, and who did not have pre-existing diabetes mellitus were included. Women in the first or second trimester, with twin (or more fetuses) pregnancies, and pre-existing diabetes were excluded. BMI and systolic and diastolic blood pressure of participants were recorded. Blood was tested for serum lipids, HbA1c, and serum adiponectin levels.

RESULTS: Thirty percent of participants had a BMI ≥ 30 kg/m². Forty-three percent of participants had HbA1c $\geq 6.5\%$. HDL levels were below normal in 30% of participants, and triglyceride levels were higher than average in about 80%. Systolic Blood Pressure was elevated in 23% of participants, and adiponectin level was low in $>60\%$ of cases. BMI was not statistically different between both groups. HDL levels and adiponectin levels were lower than normal in the diabetic group. Triglyceride levels were high in both groups. Regression analysis showed that adiponectin levels were affected by HbA1c and low HDL levels, and vice versa. Data were analyzed by SPSS version 20.

CONCLUSION: Low adiponectin levels could predict two MetS indicators in gestational diabetes and vice versa.

KEYWORDS: Adiponectin, metabolic syndrome, HDL, triglycerides, hypertension, systolic BP, diastolic BP

INTRODUCTION

Metabolic syndrome (MetS) was defined by IDF (International Diabetes Federation) as a syndrome in 2005¹. The syndrome had at least three of the following five:

- 1) obesity (BMI ≥ 30 kg/m²) or gender and ethnicity-specific cut-off values for waist circumference (WC).
- 2) History of systolic blood pressure (SBP) ≥ 130 mm Hg and diastolic blood pressure (DBP) ≥ 85 mm Hg or use of antihypertensive medication.
- 3) TG ≥ 150 mg/dL,
- 4) HDL level < 50 mg/dL for women or patients with hypercholesterolemia using the cholesterol-lowering medication, and
- 5) fasting plasma glucose (> 100 mg/dL) or known history of type 2 diabetes.

¹Department of Biochemistry, Khyber Medical College, Peshawar, KPK-Pakistan.

²Intensive Care Unit, Prince Sultan Military Medical City, Riyadh, Kingdom of Saudi Arabia.

³Department of Home and Health Sciences, Allama Iqbal Open University, Islamabad-Pakistan.

⁴Department of Nutrition, Balochistan Institute of Nephro-Urology, Quetta, Balochistan-Pakistan.

Correspondence: seeminkashif@hotmail.com
doi: 10.22442/jlumhs.2022.00984

Received: 06-09-2022

Revised: 03-11-2022

Accepted: 08-11-2022

Published Online: 14-11-2022

MetS are thought to be a predictor of chronic diseases like type 2 diabetes mellitus and hypertension. The syndrome is mainly comprised of obesity according to IDF 2005 definition, and adiposity is related to low levels of serum adiponectin^{1,2}. Hence, the researchers expected that low adiponectin levels could predict MetS and vice versa.

This study was carried out to find a simple way to predict MetS in pregnancy with the help of a single biochemical marker, i.e. adiponectin level, hence preventing the patients from going through multiple clinical and biochemical examinations

METHODOLOGY

The study was conducted from February 2015 - January 2016 in Gynecology and Obstetrics OPDs in four public and one private tertiary care hospital in Peshawar, Khyber Pakhtunkhwa, Pakistan. It was an analytical cross-sectional study. The study was done after permission was given by the IRB committee letter number 139/PG/KMC of Khyber Medical College, Peshawar, Pakistan. Purposive sampling was done. Healthy women in their third trimester of pregnancy were selected. Women with a single fetus who did not have pre-existing diabetes mellitus were included. Twin (or more fetuses) pregnancy and pre-existing diabetes (i.e. diabetic before gestation) were



excluded. One group comprised 100 control, healthy pregnant women, while the other group comprised 100 pregnant women with known gestational diabetes. BMI (body mass index) of study participants was calculated and recorded. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were also recorded for all the participants. Informed consent was taken from each participant. Blood samples were collected from each participant after 12 to 14 hours of fasting for measurements of biochemical markers. HbA1c, serum high-density lipoprotein (HDL), serum triglyceride (TAG) levels, and serum adiponectin levels were measured. Data were analyzed in SPSS version 20.

RESULTS

Two hundred pregnant females were included in the study. Of these, 100 women were non-diabetic, and the remaining 100 had gestational diabetes. About 1/4th of these participants were <19 years of age, and the BMI of 30% of the participants was ≥ 30 kg/m² (obese category). Only about 43% of the participants had HbA1c $\geq 6.5\%$, probably due to good control of diabetes. HDL levels were lower than normal limits in 30% of the participants, and serum triglyceride (TAG) levels were higher than normal in 78% of participants. SBP was higher than normal in about 25% of the participants, but DBP was higher than normal in only 4% of patients. Adiponectin level was low in more than 60% of cases (**Table I**).

Our study group was divided into diabetic and non-diabetic groups. Both groups compared the mean values of all MetS indicators and adiponectin levels. No statistically significant difference was found between the BMI of both groups. However, BMI was >30 in the non-diabetic group only but near 30 kg/m² in the diabetic group. SBP and DBP were normal and similar in both groups. HbA1c levels were higher than normal in the diabetic group, as expected. HDL levels and adiponectin levels were lower than normal in the diabetic group. No statistically significant difference in TAG levels was higher than normal in both groups (**Table II**).

Binary regression analysis showed that HbA1c predicted the adiponectin levels negatively. HDL levels predicted adiponectin levels positively after adjusting with age, gestational age, BMI, systolic and diastolic blood pressures, and TAG levels (**Table III**). Adiponectin levels could predict diabetes in pregnancy in our study after adjusting with age and gestational age, and its levels could also indicate low HDL levels (**Table III**).

DISCUSSION

Metabolic syndrome (MetS) was defined differently by many institutions, including WHO and IDF. According to IDF 2005, it was described as a syndrome that had at least three of the following five features:

1) obesity (BMI ≥ 30 kg/m²), or waist circumference $>$ cut-off values according to gender and ethnicity, 2)

SBP ≥ 130 mm Hg and DBP ≥ 85 mm Hg, or use of antihypertensive medicines, 3) TG ≥ 150 mg/dL, 4) HDL level <50 mg/dL for females, or patients using cholesterol-lowering medicines, and 5) fasting plasma glucose (>100 mg/dL), or known history of type 2 DM^{1,3}. MetS is considered a predictor of chronic diseases like type 2 DM and hypertension, so it is essential to identify it in all populations.

Table I: Characteristics of the group

Variable	Categories	Frequency	Percentage
Age	≤ 19 years	49	24.5
	>19 years	151	75.5
Status of diabetes:	Non-diabetic	100	50.0
	Diabetic	100	50.0
Gestational age	<28 weeks	59	29.5
	≥ 28 weeks	141	70.5
BMI ¹	$>18.4 < 24.9$	19.5	19.5
	$>24.9 < 30$	101	50.5
	≥ 30	60	30.0
HbA1c (%)	<6.5	115	57.5
	≥ 6.5	85	42.5
HDL ² (mg/dL)	<50	59	29.5
	≥ 50	141	70.5
TAG ³ (mg/dL)	<150	45	22.5
	≥ 150	155	77.5
Systolic BP ⁴ (mm Hg)	<130	154	77.0
	≥ 130	46	23.0
Diastolic BP (mm Hg)	<85	192	96.0
	≥ 85	8	4.0
Adiponectin level ($\mu\text{g/mL}$)	<5	123	61.5
	≥ 5	77	38.5

¹BMI=Body mass index, ²HDL=High-density lipoprotein, ³TAG= Triglycerides, ⁴BP=Blood pressure. Our study population comprised pregnant females. Fifty percent of these females had gestational diabetes. HbA1c was done to confirm diabetes^{4,5}. The HbA1c levels of the diabetic group were higher than normal, as expected, and those of non-diabetics were within normal limits (**Table II**). Still, only about 43% of the participants had HbA1c $\geq 6.5\%$, which showed reasonable control of diabetes by these patients.

The BMI of 78% of the study participants was above 25kg/m² (**Table I**); this was not beyond expectation as gestational weight gain (GWG) significantly changes the BMI even if this gain is within the recommended range⁶. However, 30% of the study population had a BMI ≥ 30 (**Table I**), which was excessive weight gain. It could be related to MetS because even if these patients had gained weight within the normal range, it reflected that the pre-pregnancy weight of these

participants was high. In any case, it showed the presence of one indicator of MetS in at least 30% of the participants of this study group. The BMI of both diabetic and non-diabetic groups was not significantly different (**Table II**).

Both groups' systolic and diastolic blood pressures were within normal levels (**Table II**). However, serum TAG levels of both groups were higher than normal, and HDL levels were lower than normal in the diabetic group only. Hyperlipidemia is a normal physiological phenomenon during pregnancy. But mechanisms that regulate this hyperlipidemia might not function well and result in adverse pregnancy outcomes like gestational diabetes or pre-eclampsia.

Table II: Differences in METS indicators between groups

Variable	Group	N	Mean	SD	P-value
BMI ¹	Non-diabetic	100	30.43	6.58	--
	Diabetic	100	28.88	5.84	
Systolic Blood Pressure (mmHg)	Non-diabetic	100	117.60	7.67	--
	Diabetic	100	119.10	8.53	
Diastolic Blood Pressure (mmHg)	Non-diabetic	100	75.00	5.55	--
	Diabetic	100	74.55	6.70	
HbA1c (%)	Non-diabetic	100	5.38	0.85	0.000
	Diabetic	100	7.35	1.13	
HDL ² (mg/dL)	Non-diabetic	100	63.58	10.27	0.000
	Diabetic	100	49.66	6.25	
TAG ³ (mg/dL)	Non-diabetic	100	215.61	93.56	--
	Diabetic	100	224.94	97.31	
Adiponectin (µg/mL)	Non-diabetic	100	9.93	4.81	0.000
	Diabetic	100	2.17	1.84	

¹BMI=Body mass index, ²HDL=High-density lipoprotein, ³TAG= Triglycerides

Abnormal lipid profiles can include raised TAG levels and decreased HDL levels⁷. TAG levels during the second trimester of pregnancy were significantly increased in GDM compared to healthy pregnant females in many studies⁷. Some studies showed low HDL level patterns in women with gestational diabetes, but others could not show changes in HDL levels even in patients with GDM⁷. However, our study showed significantly decreased HDL levels in the diabetic group (**Table II**).

Adiponectin levels decrease in conditions associated with insulin resistance, like obesity, T2DM, and gestational diabetes^{8,9}. Adiponectin reduces oxidative stress, leading to insulin resistance reduction; adiponectin increases the use of glucose and fatty acids by skeletal muscles and reduces hepatic gluconeogenesis and glycogenolysis. As expected,

our study found that serum adiponectin levels were low in the diabetic group¹⁰.

MetS is mainly comprised of obesity, according to IDF 2005, which is related to low serum adiponectin levels^{11,12}. It was expected that serum adiponectin levels would be low in obese (≥ 30 kg/m²), but this study could not show it.

Adiponectin promotes TAG storage in adipocytes and reduces the accumulation of triglycerides in the liver. Hence, it induces a decrease in circulating lipid levels, and its low levels could cause a rise in TAG levels¹³. However, adiponectin levels were low only in the diabetic group, but TAG levels were high and not significantly different in both groups (**Table II**). In our study, TAG levels could not predict serum adiponectin levels (**Table III**).

Table III: Regression analysis

Variable	p-value	OR	95% Confidence interval	
			Lower	Upper
Model 1: Adiponectin with MetS indicators p= 0.000				
HbA1c	0.002	0.002	0.00	1.02
HDL ¹	0.000	1.56	1.22	1.96
Age	0.590	--	--	--
Gestational age	0.205	--	--	--
BMI ²	0.255	--	--	--
SBP ³	0.685	--	--	--
DBP ⁴	0.311	--	--	--
TAG ⁵	0.197	--	--	--
Model 2: HbA1c with Adiponectin levels p= 0.000				
Age	0.893	--	--	--
Gestational age	0.665	--	--	--
Adiponectin levels	0.000	0.006	0.00	0.04
Model 3: HDL with Adiponectin levels p= 0.000				
Age	0.534	--	--	--
Gestational age	0.097	--	--	--
Adiponectin levels	0.000	3.19	1.86	5.47

¹HDL=High-density lipoprotein, ²BMI=Body mass index, ³SBP= Systolic blood pressure, ⁴DBP= Diastolic BP, ⁵TAG= Triglycerides

Adiponectin increases HDL levels, and its low levels could be related to low HDL levels¹⁴. Our study showed low HDL levels in the diabetic group (**Table II**). HDL levels also significantly affected adiponectin levels and vice versa (**Table III**).

Adiponectin suppresses angiotensin II to decrease blood pressure, and adiponectin possibly regulates blood pressure¹⁵. In pregnant women, low serum adiponectin levels were found to be related to pre-eclampsia. It was found that adiponectin levels fall physiologically as pregnancy advances, and it was

also found that low adiponectin level is present in obese preeclamptic women¹⁶. But in our study, despite low serum adiponectin levels in the diabetic group, both the systolic and diastolic blood pressures were normal (**Table II**).

According to this study, at least 30% of the study population was obese, about 30% of the study participants had HDL levels <50 mg/dL and about 80% of participants had TAG levels >150 mg/dL. 23% of the participants also had SBP ≥130 mm Hg. According to these findings, at least 23% of our study population fulfilled the criteria of MetS, i.e. obesity plus at least two components (according to IDF, 2005)¹. More than 60% of our study population had low adiponectin levels (**Table I**). Adiponectin levels were significantly low in the diabetic group (**Table II**). According to the literature, low adiponectin levels could predict diabetes⁸, obesity¹⁷, high TAG and low HDL levels¹⁴, and high blood pressure¹⁵. But in our study, adiponectin levels could predict blood glucose levels¹⁸ and low HDL levels⁷, but it could not predict BMI, TAG levels, or blood pressure.

Pregnancy could cause a decline in adiponectin levels due to gestational weight gain and normal hormonal changes leading to insulin resistance². Low HDL and high TAG levels could also be a part of normal physiological changes in pregnancy⁷. But as the adiponectin levels were found to be low in the diabetic group alone, and HbA1c and HDL levels showed their effect on adiponectin levels, we could assume that pregnancy alone was not a predictor of adiponectin levels. MetS probably played a definite role in our study group's decline in adiponectin levels.

One limitation of the study was that pregnancy acted as a confounder for MetS. Also, as the study was confined to pregnant women, it could not be generalized to both genders.

CONCLUSION

Low adiponectin levels could predict indicators of MetS like hyperglycemia and low HDL levels in gestational diabetes, and vice versa.

Ethical Permission: Khyber Medical College Peshawar IRB letter No. 139/PG/KMC.

Conflict of Interest: The authors have no conflict of interest to declare.

Financial Disclosure / Grant Approval: No funding agency was used for this research.

Data Sharing Statement: The data supporting this study's findings are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

AUTHOR CONTRIBUTIONS

Akhtar Y: Concept and design, drafting, final approval
Khan MA: Design, critical revision, final approval
Malik MK: Analysis, critical revision, final approval
Kashif S: Interpretation, drafting, final approval
Rehman G: Interpretation, drafting, final approval

REFERENCES

1. Aguilar-Salinas CA, Viveros-Ruiz T. Recent advances in managing/understanding the metabolic syndrome. *F1000Res*. 2019; 8: 370. doi: 10.12688/f1000research.17122.1.
2. Pheiffer C, Dias S, Jack B, Malaza N, Adam S. Adiponectin as a Potential Biomarker for Pregnancy Disorders. *Int J Mol Sci*. 2021; 22(3): 1326. doi: 10.3390/ijms22031326.
3. McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. *Clin Dermatol*. 2018; 36(1): 14-20. doi: 10.1016/j.clindermatol.2017.09.004.
4. Cs L, Tc A. HbA1c in the diagnosis and management of diabetes mellitus: an update. *Diabetes Updates*. 2019; 5. doi: 10.15761/DU.1000137.
5. Petersmann A, Muller-Wieland D, Muller UA, Landgraf R, Nauck M, Freckmann G et al. Definition, Classification and Diagnosis of Diabetes Mellitus. *Exp Clin Endocrinol Diabetes*. 2019; 127(S-01): S1-S7. doi: 10.1055/a-1018-9078. Epub 2019 Dec 20.
6. Martínez-Hortelano JA, Cavero-Redondo I, Álvarez-Bueno C, Garrido-Miguel M, Soriano-Cano A, Martínez-Vizcaíno V. Monitoring gestational weight gain and pre-pregnancy BMI using the 2009 IOM guidelines in the global population: a systematic review and meta-analysis. *BMC Pregnancy Childbirth*. 2020; 20(1): 649. doi: 10.1186/s12884-020-03335-7.
7. Yue CY, Ying CM. Epidemiological analysis of maternal lipid levels during the second trimester in pregnancy and the risk of adverse pregnancy outcome adjusted by pregnancy BMI. *J Clin Lab Anal*. 2018; 32(8): e22568. doi: 10.1002/jcla.22568. Epub 2018 May 17.
8. Yanai H, Yoshida H. Beneficial Effects of Adiponectin on Glucose and Lipid Metabolism and Atherosclerotic Progression: Mechanisms and Perspectives. *Int J Mol Sci*. 2019; 20(5): 1190. doi: 10.3390/ijms20051190.
9. Mallardo M, Ferraro S, Daniele A, Nigro E. GDM-complicated pregnancies: focus on adipokines. *Mol Biol Rep*. 2021; 48(12): 8171-8180. doi: 10.1007/s11033-021-06785-0.
10. Raza S, Ali U, Zubairi AM, Salim E. Mean Adiponectin Levels and Frequency of Hypoadiponectinemia in Gestational Diabetes Mellitus. *Pak J Med Dent*. 2021; 10(1): 37-43. doi: 10.36283/PJMD10-1/007.
11. Liu H, Yang Y, Wang Y, Tang H, Zhang F, Zhang Y et al. Ketogenic diet for treatment of intractable epilepsy in adults: A meta-analysis of observational studies. *Epilepsia Open*. 2018; 3(1): 9-17. doi: 10.1002/epi4.12098.
12. Gariballa S, Alkaabi J, Yasin J, Al Essa A. Total adiponectin in overweight and obese subjects and its response to visceral fat loss. *BMC Endocr*

- Disord. 2019; 19(1): 55. doi: 10.1186/s12902-019-0386-z
13. Nguyen Diep, Mong Thi. Adiponectin: Role in physiology and pathophysiology. *Int J Prev Med.* 2020; 11: 136. doi: 10.4103/ijpvm.IJPVM_193_20.
 14. Wattanapol P, Vichinsartvichai P, Sakoonwatanyoo P. Serum adiponectin is a potential biomarker for metabolic syndrome in peri- and postmenopausal women. *Gynecol Endocrinol.* 2020; 36(7): 620-625. doi: 10.1080/09513590.2020.1742688. Epub 2020 Apr 1.
 15. Zahary MN, Harun NS, Yahaya R. Serum adiponectin and resistin: Correlation with metabolic syndrome and its associated criteria among temiar subtribe in Malaysia. *Diabetes Metab Syndr.* 2019; 13(3): 2015-2019. doi: 10.1016/j.dsx.2019.04.048. Epub 2019 Apr 25.
 16. Adu-Gyamfi EA, Fondjo LA, Owiredo WKBA, Czika A, Nelson W, Lamptey J et al. The role of adiponectin in placentation and pre-eclampsia. *Cell Biochem Funct.* 2020; 38(1): 106-117. doi: 10.1002/cbf.3458. Epub 2019 Nov 19.
 17. Zhao S, Kusminski CM, Scherer PE. Adiponectin, Leptin and Cardiovascular Disorders. *Circ Res.* 2021; 128(1): 136-139. doi: 10.1161/CIRCRESAHA.120.314458. Epub 2021 Jan 7.
 18. Madhu S, Bhardwaj S, Jhamb R, Srivastava H, Sharma S, Raizada N. Prediction of gestational diabetes from first trimester serum adiponectin levels in Indian Women. *Indian J Endocr Metab.* 2019; 23(5): 536-39. doi: 10.4103/ijem.IJEM_319_19.

